Chris A. Rhoades

645 total citations
18 papers, 505 citations indexed

About

Chris A. Rhoades is a scholar working on Otorhinolaryngology, Oncology and Surgery. According to data from OpenAlex, Chris A. Rhoades has authored 18 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Otorhinolaryngology, 9 papers in Oncology and 8 papers in Surgery. Recurrent topics in Chris A. Rhoades's work include Head and Neck Cancer Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Salivary Gland Tumors Diagnosis and Treatment (5 papers). Chris A. Rhoades is often cited by papers focused on Head and Neck Cancer Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Salivary Gland Tumors Diagnosis and Treatment (5 papers). Chris A. Rhoades collaborates with scholars based in United States and India. Chris A. Rhoades's co-authors include David E. Schuller, J.C. Grecula, Charles L. Shapiro, Donn C. Young, Miguel A. Villalona‐Calero, Denis C. Guttridge, Michael A. Caligiuri, Gregory A. Otterson, Manisha H. Shah and John G. Kuhn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Chris A. Rhoades

18 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris A. Rhoades United States 11 256 128 119 118 111 18 505
Ya‐Hui Yu China 15 277 1.1× 242 1.9× 118 1.0× 179 1.5× 130 1.2× 53 777
Mengxia Zhang China 12 148 0.6× 133 1.0× 247 2.1× 149 1.3× 190 1.7× 36 672
Lihua Dong China 14 105 0.4× 99 0.8× 66 0.6× 131 1.1× 79 0.7× 27 410
M. Lloret Spain 20 311 1.2× 231 1.8× 70 0.6× 205 1.7× 183 1.6× 50 890
Benjamin Lyons United States 9 468 1.8× 146 1.1× 10 0.1× 182 1.5× 39 0.4× 9 868
Haldun Şükrü Erkal Türkiye 14 229 0.9× 49 0.4× 317 2.7× 232 2.0× 208 1.9× 38 647
Whitney Sumner United States 12 100 0.4× 86 0.7× 105 0.9× 61 0.5× 87 0.8× 22 373
Bella Pajares Spain 13 291 1.1× 195 1.5× 57 0.5× 112 0.9× 70 0.6× 37 592
Massimiliano Salati Italy 12 394 1.5× 197 1.5× 8 0.1× 186 1.6× 200 1.8× 25 743
Nabila Bennani-Baiti United States 9 187 0.7× 104 0.8× 14 0.1× 81 0.7× 64 0.6× 14 526

Countries citing papers authored by Chris A. Rhoades

Since Specialization
Citations

This map shows the geographic impact of Chris A. Rhoades's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris A. Rhoades with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris A. Rhoades more than expected).

Fields of papers citing papers by Chris A. Rhoades

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris A. Rhoades. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris A. Rhoades. The network helps show where Chris A. Rhoades may publish in the future.

Co-authorship network of co-authors of Chris A. Rhoades

This figure shows the co-authorship network connecting the top 25 collaborators of Chris A. Rhoades. A scholar is included among the top collaborators of Chris A. Rhoades based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris A. Rhoades. Chris A. Rhoades is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Mrózek, Ewa, Bhuvaneswari Ramaswamy, Donn C. Young, et al.. (2006). Phase II Study of Weekly Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 7(2). 141–145. 12 indexed citations
3.
Özer, Enver, J.C. Grecula, Amit Agrawal, Chris A. Rhoades, & David E. Schuller. (2006). Intensification Regimen for Advanced-Stage Resectable Hypopharyngeal Carcinoma. Archives of Otolaryngology - Head and Neck Surgery. 132(4). 385–385. 6 indexed citations
4.
Özer, Enver, J.C. Grecula, Amit Agrawal, et al.. (2006). Long-Term Results of a Multimodal Intensification Regimen for Previously Untreated Advanced Resectable Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx. The Laryngoscope. 116(4). 607–612. 17 indexed citations
5.
Lichtman, Stuart M., Donna Hollis, Antonius A. Miller, et al.. (2006). Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762). Journal of Clinical Oncology. 24(12). 1846–1851. 66 indexed citations
6.
Monk, J. Paul, Ross Waite, John G. Kuhn, et al.. (2006). Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients. Journal of Clinical Oncology. 24(12). 1852–1859. 137 indexed citations
7.
Ramaswamy, Bhuvaneswari, Anthony Elias, Nicole Kelbick, et al.. (2006). Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clinical Cancer Research. 12(10). 3124–3129. 102 indexed citations
8.
Mrózek, Ewa, Chris A. Rhoades, Jeffrey C. Allen, Erinn M. Hade, & Charles L. Shapiro. (2005). Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients. Annals of Oncology. 16(7). 1087–1093. 24 indexed citations
9.
Ramaswamy, Bhuvaneswari, Chris A. Rhoades, Donn C. Young, et al.. (2005). Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer. Breast Cancer Research and Treatment. 93(1). 67–74. 8 indexed citations
10.
Ettinger, David S., J. Pablo Arnoletti, Jon P. Gockerman, et al.. (2005). Occult primary cancer clinical practice guidelines.. PubMed. 3(2). 214–33. 2 indexed citations
11.
Malone, James P., Julie Stephens, J.C. Grecula, et al.. (2004). Disease control, survival, and functional outcome after multimodal treatment for advanced‐stage tongue base cancer. Head & Neck. 26(7). 561–572. 41 indexed citations
12.
Rhoades, Chris A., Eric H. Kraut, David Schuller, et al.. (2004). Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 22(14_suppl). 5541–5541. 3 indexed citations
13.
Rhoades, Chris A., Eric H. Kraut, David Schuller, et al.. (2004). Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 22(14_suppl). 5541–5541. 10 indexed citations
14.
Schuller, David E., J.C. Grecula, Amit Agrawal, et al.. (2002). Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer. 94(12). 3169–3178. 20 indexed citations
15.
Grecula, J.C., David E. Schuller, Roy E. Smith, et al.. (2001). Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas. Cancer Investigation. 19(2). 127–136. 6 indexed citations
16.
Grecula, J.C., Roy E. Smith, Chris A. Rhoades, et al.. (2000). Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck. Cancer. 89(12). 2587–2596. 12 indexed citations
17.
Grecula, J.C., David E. Schuller, Chris A. Rhoades, et al.. (1999). Intensification Regimen 2 for Advanced Head and Neck Squamous Cell Carcinomas. Archives of Otolaryngology - Head and Neck Surgery. 125(12). 1313–1313. 18 indexed citations
18.
Triozzi, Pierre L., Chris A. Rhoades, & Donald Thornton. (1995). High-dose chemotherapy for breast cancer. Cancer Treatment Reviews. 21(3). 185–198. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ya‐Hui Yu Breakdown of academic impact, for papers by Mengxia Zhang Breakdown of academic impact, for papers by Lihua Dong Breakdown of academic impact, for papers by M. Lloret Breakdown of academic impact, for papers by Benjamin Lyons Breakdown of academic impact, for papers by Haldun Şükrü Erkal Breakdown of academic impact, for papers by Whitney Sumner Breakdown of academic impact, for papers by Bella Pajares Breakdown of academic impact, for papers by Massimiliano Salati Breakdown of academic impact, for papers by Nabila Bennani-Baiti
Rankless by CCL
2026